Template:Available forms of progesterone

From blackwiki
Revision as of 07:33, 20 October 2020 by imported>Monkbot (→‎top: Task 17 (BRFA trial): replace to-be-deprecated: |name-list-format= (2× replaced; usage: 2 of 2);)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Available forms of progesterone[sources 1][lower-alpha 1]

Route Form Dose Brand name Availability[lower-alpha 2]
Oral Capsule 100, 200, 300 mg Prometrium[lower-alpha 3] Widespread
Tablet (SR) 200, 300, 400 mg Dubagest SR[lower-alpha 3] India
Sublingual Tablet 10, 25, 50, 100 mg Luteina[lower-alpha 3] Europe[lower-alpha 4]
Transdermal Gel[lower-alpha 5] 1% (25 mg) Progestogel Europe
Vaginal Capsule 100, 200 mg Utrogestan Widespread
Tablet 100 mg Endometrin[lower-alpha 3] Widespread
Gel 4, 8% (45, 90 mg) Crinone[lower-alpha 3] Widespread
Suppository 200, 400 mg Cyclogest Europe
Ring 10 mg/day[lower-alpha 6] Fertiring[lower-alpha 3] South America[lower-alpha 7]
Rectal Suppository 200, 400 mg Cyclogest Europe
Uterine IUD 38 mg Progestasert Discontinued
Intramuscular
injection
Oil solution 2, 5, 10, 20, 25,
50, 100 mg/mL
Proluton[lower-alpha 3] Widespread
Aq. susp. 12.5, 30, 100 mg/mL Agolutin[lower-alpha 3] Europe[lower-alpha 8]
Emulsion 5, 10, 25 mg/mL Di-Pro-Emulsion Discontinued
Microsph. 20, 100 mg/mL ProSphere[lower-alpha 3] Mexico
Subcutaneous Aq. soln. (inj.) 25 mg/vial Prolutex Europe
Implant 50, 100 mg Proluton[lower-alpha 3] Discontinued
Intravenous Aq. soln. (inj.) 20 mg/mL Primolut Discontinued
Sources and footnotes:
  1. This table only includes products where progesterone is the sole active ingredient.
  2. See also: Progesterone (medication) § Availability
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 Other brand names exist.
  4. Specifically in Poland and Ukraine.
  5. For local application to the breasts; negligible systemic effect.
  6. One progesterone vaginal ring provides 10mg of progesterone each day for 3 months.
  7. Specifically in Chile, Ecuador, and Peru.
  8. Specifically the Czech Republic and Slovakia.
Template documentation

See also

References

  1. "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 26 July 2018.
  2. Engel J, Kleemann A, Kutscher B, Reichert D (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 1145–. ISBN 978-3-13-179275-4.
  3. Becker, Kenneth L. (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 2168–. ISBN 978-0-7817-1750-2. Unknown parameter |name-list-style= ignored (help)
  4. Anita MV, Jain S, Goel N (31 July 2018). Use of Progestogens in Clinical Practice of Obstetrics and Gynecology. JP Medical Ltd. pp. 4–. ISBN 978-93-5270-218-3.
  5. Sauer, Mark V. (1 March 2013). Principles of Oocyte and Embryo Donation. Springer Science & Business Media. pp. 7, 117–118. ISBN 978-1-4471-2392-7. Unknown parameter |name-list-style= ignored (help)
  6. Elder K, Dale B (2 December 2010). In-Vitro Fertilization. Cambridge University Press. pp. 26–. ISBN 978-1-139-49285-0.
  7. https://web.archive.org/web/20191230051017/https://mx.prvademecum.com/medicamento/prosphere-11003/
  8. Heinrich Kahr (8 March 2013). Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. pp. 21–. ISBN 978-3-7091-5694-0.
  9. Basic Sex Hormone Therapy. Schering A.G. 1962. p. 96.
  10. Current Medicine and Drugs. 1962. p. 40. Primolut Intravenous (Schering A.G. Berlin)
  11. Haleem S, Khan MI (March 2015). "Changing Indian Market Trends of NMP: A Review" (PDF). International Journal of Pharma Research & Review. 4 (3): 28–30. ISSN 2278-6074.